Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Peptide vaccines aim to enhance T-cell responses against tumor antigens for cancer immunotherapy.
• Current native peptide vaccines often show limited efficacy in preventing tumor growth.

Purpose of the Study:

• To investigate how to optimize peptide vaccines for improved T-cell responses in a mouse-colon tumor model.
• To identify characteristics of peptide variants that correlate with effective antitumor immunity.

Main Methods:

• Assembled a set of peptide variants with similar MHC affinity but differing in TCR interaction affinity.
• Vaccinated mice with variant peptides and assessed T-cell responses and tumor growth.
• Analyzed T-cell reactivity to both variant peptides and native tumor antigens in vitro and in vivo.

Main Results:

• Variant peptides stimulating a larger proportion of endogenous T cells specific for the native tumor antigen generated effective antitumor responses.
• Some variant peptides, while potent in vitro, failed to elicit protective immunity in vivo.
• Effective vaccines expanded T cells that responded to the wild-type antigen (cytokine production, target cell killing).

Conclusions:

• Peptide-variant vaccines are most effective when they engage a broad repertoire of tumor-specific T cells.
• The ability of a peptide variant to stimulate a diverse T-cell population is crucial for in vivo efficacy.
• Optimizing peptide variants requires consideration of their interaction with the endogenous T-cell repertoire, not just specific T-cell clones.